Literature DB >> 34181109

PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.

Meghana Parsi1, Milap H Desai2, Devashish Desai3, Sachi Singhal3, Pushti M Khandwala3, Rashmika R Potdar4.   

Abstract

Although management of advanced prostate cancer is evolving, a lot of work remains to be done for patients who have exhausted all options. Molecular targeting of prostate specific membrane antigen (PSMA) is valuable not only for diagnostic but also for therapeutic reasons. PSMA is thus considered to be useful in a theranostic approach. PSMA scans are upcoming diagnostic modalities which detect metastatic lesions that are missed by conventional imaging modalities. PSMA ligand therapy is also an upcoming treatment modality that has been proven to be beneficial with minimal toxicity in patients with advanced prostate cancer that have progressed on prior therapy. In this review article, we summarize the current knowledge regarding PSMA diagnostics and PSMA ligand therapies and discuss their implication in the treatment of advanced prostate cancer.

Entities:  

Keywords:  PSMA; PSMA scans; Prostate cancer; Radioligand; Theranostics

Mesh：

Substances：

Year:  2021        PMID： 34181109     DOI： 10.1007/s12032-021-01537-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  70 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

3.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Parker; S Gillessen; A Heidenreich; A Horwich
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

4.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

5.  Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.

Authors:  M Kawakami; J Nakayama
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

6.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.

Authors:  D G Bostwick; A Pacelli; M Blute; P Roche; G P Murphy
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

7.  Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.

Authors:  Tomomi Kusumi; Takuya Koie; Masanori Tanaka; Kazuhito Matsumoto; Fuyuki Sato; Akinori Kusumi; Chikara Ohyama; Hiroshi Kijima
Journal:  Pathol Int       Date:  2008-11       Impact factor: 2.534

Review 8.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

9.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

10.  Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.

Authors:  Kirsten Bouchelouche; Peter L Choyke; Jacek Capala
Journal:  Discov Med       Date:  2010-01       Impact factor: 2.970
View more
  5 in total

Review 1.  Prostate cancer in transgender women: considerations for screening, diagnosis and management.

Authors:  Fionnuala Crowley; Meredith Mihalopoulos; Simita Gaglani; Ashutosh K Tewari; Che-Kai Tsao; Miroslav Djordjevic; Natasha Kyprianou; Rajveer S Purohit; Dara J Lundon
Journal:  Br J Cancer       Date:  2022-10-19       Impact factor: 9.075

Review 2.  The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers.

Authors:  Catarina Leitão; Bárbara Matos; Fátima Roque; Maria Teresa Herdeiro; Margarida Fardilha
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

3.  Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene.

Authors:  Kosuke Mizutani; Kyojiro Kawakami; Yasunori Fujita; Taku Kato; Manabu Takai; Daiki Kato; Koji Iinuma; Takuya Koie; Masafumi Ito
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

4.  Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.

Authors:  Ondrej Vit; Mayank Patel; Zdenek Musil; Igor Hartmann; Zdenek Frysak; Markku Miettinen; Karel Pacak; Jiri Petrak
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

Review 5.  Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.

Authors:  Jinxing Huang; Kai Xiao
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.